Studies have evaluated several markers for potential roles in shaping, or predicting therapeutic responses including PD-L1 and PD-1 expression pattern, genetic mutations and neoantigens in cancer cells, cancer epigenetics, effector T cell landscape, and microbiota but results remain inconclusive14,17–19. This evidence concerns the gene RPL17 and cancer.